DLA Piper advises TD Cowen as underwriter in MdxHealth’s US$40 million public offering of ordinary shares
DLA Piper advised TD Cowen, a leading investment bank and subsidiary of TD Securities, as a lead underwriter in the public offering of 20,000,000 ordinary shares from MdxHealth SA, a commercial-stage precision diagnostics company. The gross offering price totaled US$40 million. TD Cowen and William Blair acted as joint book-running manager alongside BTIG, LLC and Lake Street Capital Markets, which acted as passive bookrunners for the offering.
Mdxhealth provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The company intends to use the net proceeds from the offering for general corporate and working capital purposes, including to fund product development efforts and commercial activities
“It was a pleasure to partner with the TD Cowen and William Blair teams in this important transaction for MDx,” said Anna Spence, the DLA Piper partner who led the deal team.
In addition to Spence (New York, Raleigh), the DLA Piper team included associates Bianca LaCaille and Sarah Cooper (both in Seattle).
DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.
DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.
